> top > docs > PMC:7784830 > spans > 24721-26016 > annotations

PMC:7784830 / 24721-26016 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
412 776-784 Species denotes patients Tax:9606
413 614-623 Species denotes influenza Tax:11309
414 637-643 Chemical denotes starch MESH:D013213
415 910-914 Chemical denotes ODFs
416 983-988 Chemical denotes water MESH:D014867
417 431-439 Disease denotes COVID-19 MESH:C000657245
418 794-803 Disease denotes dysphagia MESH:D003680
419 807-826 Disease denotes Parkinson’s disease MESH:D010300

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T8 794-803 Phenotype denotes dysphagia http://purl.obolibrary.org/obo/HP_0002015

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T195 125-280 Sentence denotes For instance, one of the studies reported that 38 billion USD would be spent on transportation and administration of 18 vaccines in 94 countries [123,124].
T196 281-367 Sentence denotes Therefore, there is a need for alternate dosage forms that can help reducing the cost.
T197 368-523 Sentence denotes For instance, Vaxart Inc is developing recombinant vaccine for COVID-19 in tablet formulation using its patent protected technology called VAAST [107–109].
T198 524-678 Sentence denotes RP Scherer Technologies LLC is also developing a tablet formulation (fast dissolving) for influenza vaccine with starch as immune stimulating agent [125].
T199 679-898 Sentence denotes Tablets are highly traditional and conventional dosage forms that are difficult to administer to patients who have dysphagia or Parkinson’s disease and are extremely difficult to administer to pediatrics and geriatrics.
T200 899-1000 Sentence denotes Therefore, ODFs remain as an alternate choice of administration as they do not need water to consume.
T201 1001-1072 Sentence denotes Most importantly, they are easy to transport from one place to another.
T202 1073-1196 Sentence denotes Israel’s Migal Galilee Research Institute is actively developing a vaccine that is administered via oromucosal route [104].
T203 1197-1295 Sentence denotes Some of the vaccine preparations that are successfully formulated as ODFs are provided in Table 6.